We previously identified a novel MLL5 isoform MLL5β, which was essential for E6 and E7 transcriptional activation in HPV16/18-associated cervical cancers. In this report, we investigated the potential of RNAi-mediated silencing of MLL5β through the use of MLL5β-siRNA as a novel therapeutic strategy for HPV16/18-positive cervical cancer. We observed concurrent down-regulation of E6 and E7 after MLL5β silencing, leading to growth inhibition via the activation of apoptosis and senescence in the HeLa cell model. This corresponded with the enhanced anti-tumor effects of MLL5β-siRNA compared to E6-or E7-siRNA single treatments. Significant reduction in tumor size after MLLβ-siRNA treatment in the HeLa xenograft tumor model further emphasized the importance of MLL5β in HPV16/18-associated tumor growth and the potential of RNAi therapeutics that target MLL5β. We also identified MLL5β as a modulator of cisplatin's gamma-irradiation (IR) sensitization properties. We observed that while MLL5β silencing alone was enough to evoke cisplatin-like IR sensitization in tumor cells in vitro, overexpression of MLL5β inhibited cisplatin's ability to sensitize HeLa cells to IR-induced cytotoxicity. MLL5β-siRNA-IR co-treatment was also observed to enhance tumor growth inhibition in vivo. Taken together, our findings highlight the potential of targeted silencing of MLL5β via the use of MLL5β-siRNA as a novel therapeutic strategy and propose that MLL5β-siRNA could be a viable alternative for cisplatin in the current cisplatin-based chemotherapeutics for HPV16/18-associated cervical cancers.
INTRODUCTION
the use of cisplatin is not without its disadvantages. The lack of specificity for cancer cells and the increasing incidence of cisplatin resistance have greatly limited its use (22). Therefore there is an urgent need for the identification of novel molecular targeted therapeutic strategies.
Due to the prominent roles of E6 and E7 in tumorigenesis and specificity to HPV-related cancer cells, there has been intense interest in targeting these two oncoproteins as a potential therapeutic strategy for HPV-positive cervical cancer (26, 27) . In recent years, the development of RNA interference (RNAi) based strategies for disease treatment has gained prominence with many at various stages of clinical trials (28) . With its precise targeting of specific oncogenes, RNAi stands out as one of the most favourable cancer therapeutics in the near future. In the development of RNAi-based therapeutic strategies for HPV-related cervical cancers, efforts have been focused on the potential of direct suppression of E6 and E7 expression through their siRNAs (26, 27, 29-32).
Our laboratory has recently discovered an HPV16/18-positive cell-specific novel protein isoform of Mixed Lineage Leukaemia 5 (MLL5β), essential for the activation of E6 and E7 gene expression in these cells (33) . We reported that MLL5β was detected in HPV16/18-positive cell lines and primary human cervical carcinoma specimens. We also identified that MLL5β activates the transcription of both the E6 and E7 oncogenes through the formation of a complex with AP-1 at the distal AP-1 binding site of the HPV long control region (LCR). RNAi-mediated silencing of MLL5β via the use of a MLL5β-specific siRNA down-regulated both E6 and E7 gene and protein expression levels, leading to the restoration of p53 and pRb. Observing this combinatory effect of MLL5β silencing on both E6 and E7 expression in HPV16/18-positive cells, we are interested in the potential application of RNAi therapeutic targeting of MLL5β as a treatment strategy for HPV16/18-positive cervical cancer.
In this report, we assessed the effects of RNAi-targeted silencing of MLL5β on HPV16/18-positive tumor growth in vitro and in vivo. The effectiveness of MLL5β silencing on tumor growth suppression was also compared with the proposed use of RNAi therapeutics targeting E6 and E7. specifically target each HPV subtype. Scrambled-siRNA was used as a control. MLL5β cDNA sequence was amplified from HeLa cDNA by polymerase chain reaction and the PCR amplicons were digested with BamHI and NotI and cloned into pEF6/V5-His vector (Invitrogen) to obtain the FLAGtagged MLL5β-expressing vector (pEF6-FLAG-MLL5β). shRNA and plasmid transfections were carried out using the calcium phosphate-based transfection method.
Clonogenic, attachment and soft agar assay
shRNA was transfected into cells and subjected to 72 h of hygromycin (500 μg/ml) selection 24 h after transfection. Surviving cells were harvested for clonogenic, attachment and soft agar assays. For clonogenic assay, 400 cells were added into each well of a 6-well plate with hygromycin media (500 μg/ml). The plate was incubated for 20 days with changing of fresh hygromycin media every 3 days.
The colonies formed were fixed with methanol and stained with 0.5 % crystal violet (Sigma-Aldrich).
Colonies were observed under microscope and the percentage of surviving clone was calculated as the number of successful clones over total cells added. For attachment assay, 10000 cells were plated in to a 24-well and allowed to attach for 4 h. After 4 h, attached cells are trypsinized and counted. For each shRNA set, three wells were plated with 10000 each. Percentage of attached cells was counted for each well and the average was taken. Results are presented as mean of three experiments ± SD. p < 0.05 is taken to be statistically significant.
For soft agar assay, DMEM 2X and 0.6% as well as 0.8 % agarose solutions were prepared and kept warm at 40 °C. 500 μl of DMEM 2X was mixed with 500 μl of 0.8 % agarose and pipetted into a 6-well plate as the base layer for each well. This was allowed to cool and solidify for 30 min in an incubator. 800 cells were resuspended in 500 μl of DMEM 2X and mixed with 500 μl of 0.6 % agarose before being added on top of the settled base layer. 500 μl of hygromycin media was added to each well after the top layer has cooled and formed a semi-solid matrix. The plate was incubated for 30 days with the addition of 500 μl hygromycin media every 3 days. Colonies were fixed and stained as described above. Total RNA was extracted with TRIzol (Invitrogen). RNA was treated with DNase I (Ambion) prior to cDNA synthesis using the First Strand cDNA Synthesis Kit (Invitrogen). Gene expression was measured with iQ5 qPCR (Biorad) using SYBR Green PCR Master Mix (BioRad) and in-house designed primers (Supplementary Table 2 ).
Senescence assay
HeLa cells were plated in 6-well plate and the appropriate siRNA was transfected into the cells. Cells were cultured for 10 days with transfection of siRNA every 3 days. After 10 days, cells were washed and stained using the Senescence Cells Histochemical Staining Kit (Sigma-Aldrich). The number of senescent cells (stained blue) was calculated as a percentage of total cells in each sample.
Trypan blue exclusion assay
To assess the viability of cells after siRNA transfection, trypan blue exclusion assay was performed.
Cells were washed with PBS and both attached and unattached cells collected and pelleted. Cells were resuspended in PBS and mixed with equal volume of trypan blue (Sigma-Aldrich). Both live and dead cells were counted. Cell viability was calculated as the percentage of the living cells divided by total number of cells. Experiment was performed in triplicates.
Cytotoxicity assay
To assess the toxicity caused by either cisplatin or siRNA, coupled with or without gammairradiation, cytotoxicity assay was performed with Cyto96 Non-Radioactive Cytotoxicity Assay (Promega). Each set was carried out in triplicates. For both siRNA and cisplatin-treated samples, the cells were harvested for assay 24 h after gamma-irradiation treatment.
In vivo tumor xenograft mouse study
Experiments were performed in accordance with NIH and IACUC guidelines for animal use using 6-week-old BALB/c immunoincompetent nude mice (Genscript). For tumor formation, a suspension containing 5×10 6 HeLa cells in 100 µl of PBS plus matrigel (1:1) were injected subcutaneously in the right flank of nude mice. To investigate the effects of the various siRNAs on tumor growth, the tumor-bearing mice were randomly assigned into 4 groups (5 mice/group) and given intra-tumoral injections of specific siRNAs every other day for 20 days. In particular, each group received intratumoral injections of either scrambled-, E6-, E7-or MLL5β-siRNA at a dosage of 10 μg/mouse.
To investigate the IR sensitization effects of MLL5β-siRNA on tumor growth in vivo, the tumorbearing mice were randomly assigned into 4 groups (6 mice/group). Groups 1 and 2 were injected (intra-tumoral) with 10 μg/mouse MLL5β-siRNA every other day for a 20-day period, and mice in Group 2 were irradiated with 1 Gy of IR on days 9 and 13 after siRNA treatment. Groups 3 and 4
were subjected to the same protocol where both groups were similarly injected with 10 μg/mouse scrambled-siRNA in place of MLL5β-siRNA over the same 20-day period and mice in Group 4 subjected to IR as per the protocol for Group 2. 
Statistical Analysis
All data are presented as mean ± SD. 
RESULTS

Targeted silencing of MLL5β reduces the colony-formation ability of HeLa cells in vitro.
To access the potential of MLL5β-targeted silencing as a therapeutic strategy for HPV16/18-positive cervical cancer, we first looked at the anti-tumor effects of the RNAi-mediated silencing of MLL5β in vitro using the HeLa model. HeLa cells have been chosen for our in vitro studies as they display consistently high transfection efficiencies (34) . Clonogenic assay was first performed using shRNAmediated RNAi, to test the effects of MLL5β silencing on cell survival and proliferation. As shown in Figure 1A , targeted silencing of MLL5β significantly reduced the number of colonies formed (more than 90% reduction compared to non-treatment/empty). This reduction in colony numbers was found to be greater than the targeted silencing of either E6 (~ 70% reduction) or E7 (~ 40% reduction) alone.
As HeLa cells were pre-transfected with the respective shRNAs, the ability of these cells to attach to the plate was also analysed. It was observed that after 4 h, the ability of cells pre-transfected with MLL5β-shRNA to attach to the plate was significantly reduced compared to scrambled-shRNA transfected cells. Similar to the observations in Figure 1A , the ability of E6-and E7-shRNA transfected cells to attach were also reduced but to a smaller extent compared to MLL5β-shRNA transfected cells (Supplementary Figure S1 ). These data suggest that the observed reduction in colony numbers after MLL5β-shRNA expression could also be a result of the inability of these cells to attach to the plate. Therefore to ascertain that MLL5β silencing affected the viability and proliferative ability of the cells, a soft agar assay was carried out. In this assay, the ability of the cells to attach is not a pre-requisite for colony formation. Upon silencing of MLL5β, HeLa cells failed to form any observable colonies compared to those treated with empty vector ( Figure 1B ). As expected, E6 and E7 silencing in HeLa cells also failed to form any observable colonies.
Enhanced anti-tumor effect of MLL5β-targeted silencing is a consequence of the induction of both apoptosis and senescence as a result of concurrent E6 and E7 down-regulation.
It has been established that E6 knockdown induces apoptosis in HPV16/18-positive cell lines while E7 knockdown leads to senescence (12, 30, 35) . We have previously reported that MLL5β is essential in the activation of both the E6 and E7 transcription in HPV16/18-positive cells (33) . With these observations, we hypothesized that the more pronounced anti-tumor effects of MLL5β-targeted silencing in HeLa cells was due to the combined effects of both apoptosis and senescence as a consequence of the down-regulation of both E6 and E7 transcript levels. To validate this, we first determined the effects of MLL5β knockdown on the expression of the E6 and E7 transcripts levels.
As expected, knockdown of MLL5β resulted in the concurrent reduction of both E6 and E7 transcript levels in HeLa cells ( Figure 1C , left panel). This was accompanied by the concurrent down-regulation of both E6 (~50% decrease) and E7 (~80% decrease) protein levels ( Figure 1C , right panel, Supplementary Figure S2 ). We next sought to investigate if the observed down-regulation of both E6 and E7 levels after MLL5β knockdown resulted in both apoptosis and senescence. First, the degree of apoptosis after MLL5β, E6 or E7 knockdown in HeLa cells was determined via the analysis of apoptotic marker cleaved-PARP in western blotting analysis. A marked accumulation of cleaved-PARP was observed after MLL5β and E6 knockdown but not after E7 knockdown ( Figure 1D ).
Next, senescent levels after MLL5β, E6 or E7 knockdown were assessed. We observed a high percentage of cells in senescence only after MLL5β and E7 knockdown while E6 knockdown induced little effect after 1 week ( Figure 1E ). These observations strongly suggest that the enhanced antitumor effects of MLL5β-targeted silencing compared to E6 or E7 silencing alone is due to the concurrent induction of apoptosis and senescence as a result of both E6 and E7 down-regulation. MLL5β-siRNA compared to the HPV16/18-negative C33A and normal diploid WI38 cells (Figure 2A and B). While all the siRNA treatments have minimal effects on C33A and WI38 indicating their specificity for HPV16/18-positive cells, the reduction of cell viability for HPV16/18-positive cell lines was more pronounced in MLL5β-siRNA-treated cells when compared to either E6-or E7-siRNA treatment alone. This observation further suggests the enhanced efficacy of MLL5β-targeted silencing compared to the silencing of E6 or E7 alone. It was also of interest to note the HPV-subtype specificity of E6-and E7-siRNA treatment, where HPV16-positive SiHa cells were more sensitive to the growth inhibitory effects of the HPV16 E6-and E7-siRNAs and HPV18-positive HeLa was more sensitive to the HPV18 E6-and E7-siRNAs.
RNAi-targeted silencing of MLL5β mediated by
MLL5β-siRNA exhibits anti-tumor effects in vivo.
Next, the anti-tumor properties of MLL5β-siRNA were determined in vivo. Using a nude mice HeLa xenograft model, the effects of scrambled-, E6-, E7-or MLL5β-siRNA injected intra-tumorally on tumor growth rate were monitored over 20 days. Consistent with the results observed in vitro, MLL5β-siRNA showed the highest tumor-suppressive ability compared to E6-or E7-siRNA treatment alone when a graph of average tumor volume increase at each reading was calculated and plotted ( Figure 2C ). The average-fold increase in tumor volume was also calculated and MLL5β-siRNA-treated tumors registered an approximately 0.5-fold increase in tumor volume after the 20-day treatment period. This is significantly (p<0.001) smaller than the 1.79-fold increase observed in the scrambled-siRNA-treated group as well as tumors treated with either E6-or E7-siRNA alone, which averaged a 0.94 and 1.31-fold increase in tumor volume respectively ( Figure 2D ). Average tumor doubling time (DT), a widely used measure of tumor growth after therapy in the clinics, was also calculated for each group and presented in Table 1 . Consistent with the above results, the average DT after MLL5β-siRNA treatment was slowed to approximately 38 days compared to the 14.6 days of the scrambled-siRNA-treated group. This growth was also significantly slower than that of either E6- 
siRNA (28.6 days) or E7-siRNA (21.2 days) treatment alone. Taken together, these data strongly suggest the potential of MLL5β-siRNA as a potential RNAi-based therapeutic agent for HPV16/18-positive cervical cancer.
MLL5β is a modulator of cisplatin's gamma-irradiation sensitization property.
The current standard therapy for cervical cancer includes chemotherapy using platinum-based derivatives such as cisplatin in combination with radiotherapy. Cisplatin is widely believed to exert some of its anti-tumor actions through the activation of the p53-dependent apoptotic pathway by down-regulating E6, and stabilizing p53 expression (19, (23) (24) (25) Next, a similar cytotoxicity assay was conducted using siRNA treatment in place of cisplatin. In this assay, while IR induced significant increases in cytotoxicity across all cell lines treated with the various siRNAs, only MLL5β-siRNA showed enhanced cisplatin-like IR sensitization effects in both SiHa and HeLa cells. This was in contrast to E6-siRNA induced IR sensitization which was subtype specific, while E7-siRNA-treated cells showed minimal IR sensitization effects ( Figure 4B ). Figure 4A , MLL5β-siRNA induced < 20% cytotoxicity in HPV16/18-negative cells with or without IR, suggesting the selectivity and specificity of MLL5β-siRNA on cytoxicity and IR sensitization for HPV16/18-positive cells.
Compared to
MLL5β-siRNA-IR co-treatment showed enhanced tumor growth inhibition in vivo.
Finally, to investigate the potential application of MLL5β-siRNA-IR combinational therapy, we next validated the ability of MLL5β-siRNA to work with IR to inhibit tumor growth in vivo using the previously established HeLa xenograft tumor model ( Figure 2C was also calculated for each group and presented in Table 2 . Again, consistent with the above results, it was revealed that the average DT of MLL5β-siRNA-IR combinatorial therapy was significantly longer than that of either MLL5β-siRNA or IR single treatment.
DISCUSSION
We have previously identified a novel MLL5 isoform, MLL5β which was found to activate E6/E7 expression in HPV16/18-positive cells through the distal AP-1 site in the long control region (LCR) (33) . Knocking down MLL5β via a siRNA-duplex designed specifically to target only the isoform, down-regulated E6 and E7, at both transcript and protein levels. In this study, we report the selective pro-apoptotic and growth-suppressing properties of this MLL5β-specific siRNA (MLL5β-siRNA) on HPV16/18-positive cells. MLL5β-siRNA promoted cell death and suppressed the growth of cancer cells, in vitro and in vivo. These MLL5β-siRNA anti-cancer properties were related to the induction of both apoptosis and senescence as a result of its ability to down-regulate both E6 and E7 levels. We also assessed the effectiveness of MLL5β-siRNA as an alternative to cisplatin in the sensitization of The current gold standard treatment for cervical cancer includes chemotherapy using cisplatin, in combination with IR-radiotherapy. This chemoradiotherapy targets rapidly dividing cancer cells by inducing DNA damage, triggering the up-regulation of p53 activating p53-dependent apoptotic cascades. However, the major drawback of this current strategy is the lack of tumor cell specificity resulting in a multitude of unwanted side effects due to their cytotoxic effects on non-tumor cells.
Besides, some patients eventually develop resistance to cisplatin, greatly limiting its effectiveness (22, 37, 38) . Therefore, there is an urgent need for the development of more novel and better molecularbased therapeutics in HPV16/18-associated cervical cancer therapy.
Recently, targeted-therapy via RNA interference (RNAi) has emerged as a promising treatment strategy for many types of cancer, with a number already in clinical trials (39, 40 ). The precise targeting of specific genes by RNAi mediated by siRNAs is a major advantage of such therapy, and it presents as one of the most favourable cancer treatment options in the near future. HPV-induced tumors have emerged as an ideal model system for the therapeutic use of RNAi due to the exclusive expression of the E6 and E7 oncogenes in cancer cells. As such, many efforts have been made to explore the therapeutic potentials of siRNAs targeting the E6 and E7 oncogenes in HPV-induced cancers. However, due to the highly specific nature of the siRNAs, subtyping of the HPV involved has to be accurately performed before the corresponding E6-or E7-siRNAs can be administered.
Moreover, a number of HPV infections are reported to be heterogeneous in nature with the infection of multiple subtypes in one individual (41) . This makes the selection of a suitable siRNA a challenge. 
E7 expression, it has an enhanced anti-tumor effect compared to the use of E6-or E7-siRNA alone.
As shown in both in vitro and in vivo assays, the combined effects on E6 and E7 expression of MLL5β-siRNA on tumor cells resulted in the activation of both the apoptotic and senescence pathways in these cells, resulting in an enhanced tumor growth inhibition (Figure 1 and 2) . Moreover, since MLL5β activates E6/E7 expression in both HPV16 and HPV18 subtypes, it can be employed as a therapeutic strategy in both HPV16-and HPV18-positive tumors, circumventing the subtype specificity issue of E6-or E7-siRNA-based therapy. Secondly, in comparison to cisplatin, cytotoxic effects of MLL5β-siRNA are highly specific to HPV16/18-positive cancer cells because its target, MLL5β, is expressed exclusively in these cancer cells (Figure 2A and B) . This high specificity of the MLL5β-siRNA significantly lowers the adverse side effects brought about by cisplatin's cytotoxic effects on non-tumor cells. Besides, we also established that cisplatin exerts its anti-cancer effect through a mechanism that involves MLL5β ( Figure 3A and B) . Therefore, by targeting MLL5β directly using the MLL5β-siRNA, we could achieve a comparable anti-cancer effect compared to cisplatin but with minimal cytotoxicity on non-tumor cells.
In this study, we also explored the effectiveness of MLL5β-siRNA-IR combinational therapy in vitro and in vivo. 
In summary, we have successfully demonstrated the potential of RNAi-targeted silencing of MLL5β via the use of MLL5β-specific siRNA as a novel therapeutic strategy for HPV16/18-positive human cervical cancer. The use of MLL5β-siRNA offers higher tumor specificity compared to the conventional treatment of using cisplatin and better efficacy compared to the proposed method of employing E6-and E7-specific siRNAs. Our study highlighted that MLL5β-siRNA-mediated targeted silencing of MLL5β induces both apoptosis and senescence in cancer cells via its combined action on both E6 and E7 expression. We also offered a possible mechanism for cisplatin-induced IR sensitization effects through its action on MLL5β and suggest the potential of MLL5β-siRNA as an alternative to cisplatin in the treatment of HPV16/18-related cervical cancers. 
